Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients

The mammalian target of rapamycin complex 1 (mTORC1) is an attractive target for HER-2 positive breast cancer therapy because of its key role in protein translation regulation, cell growth and metabolism. We present here a metabolomic investigation exploring the impact of mTOR inhibition on serum me...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Jobard, Elodie, Trédan, Olivier, Bachelot, Thomas, Vigneron, Arnaud M., Aït-Oukhatar, Céline Mahier, Arnedos, Monica, Rios, Maria, Bonneterre, Jacques, Diéras, Véronique, Jimenez, Marta, Merlin, Jean-Louis, Campone, Mario, Elena-Herrmann, Bénédicte
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5663537/
https://ncbi.nlm.nih.gov/pubmed/29137365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18784
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires